[ TRANSACTION RECORD ]

JPMorgan Chase & Co. Investment in Prometheus Biosciences Inc. — 2023

VERIFIED VECTOR ID: 002133 · tx-229
M SOURCE NODE — FUNDER
JPMorgan Chase & Co.
Finance United States
$10,800,000,000
EQUITY
16/06/2023
Q DESTINATION NODE — RECIPIENT
Prometheus Biosciences Inc.
Company United States
Amount (USD)
$10.8B
Flow Type
EQUITY
Transaction Date
16/06/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity JPMorgan Chase & Co.
AUM 3900000
HQ Location United States
Sector Finance
Recipient Profile [ Q ]
Entity Prometheus Biosciences Inc.
Entity Type Company
Jurisdiction United States
Intelligence Note

Merck & Co. completed the 10.8 billion dollar acquisition of Prometheus Biosciences to gain access to a promising precision medicine therapy for immune-mediated diseases. This transaction accelerates Merck’s expansion into the immunology sector through advanced biotech innovation. The deal highlights the high institutional value of targeted pharmaceutical platforms.

Σ
Primary Forensic Source https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences-inc/
✓ SOURCE LINKED